THDB(SH:600867)2022-08-30 16:00Financial Performance - The net profit attributable to the parent company's shareholders for the first half of 2022 was CNY 1,182,565,653.56[3]. - The company's operating revenue for the first half of the year was ¥1,387,525,870.51, a decrease of 16.53% compared to the same period last year[17]. - Net profit attributable to shareholders increased by 75.49% to ¥1,182,565,653.56, driven by gains from the sale of shares in Te Bao Bio[17][19]. - The net profit after deducting non-recurring gains and losses was ¥441,299,473.10, down 32.67% year-on-year[17]. - Basic earnings per share rose to ¥0.59, reflecting a 78.79% increase compared to the previous year[18]. - The weighted average return on net assets increased by 6.00 percentage points to 17.69%[18]. - The total profit for the same period was CNY 1,383.29 million, an increase of 74.33% year-on-year[39]. - The company reported a total comprehensive income of CNY 1,184,488,919.00 for the first half of 2022, compared to CNY 700,664,943.10 in the previous year[121]. Dividend Distribution - The proposed cash dividend is CNY 2.50 per 10 shares (including tax), totaling CNY 499,544,648.00 (including tax)[3]. - The cash dividend represents 42.24% of the net profit attributable to the parent company's shareholders for the period[3]. - The company plans to maintain the distribution ratio even if there are changes in the total share capital before the dividend distribution date[3]. - The profit distribution plan has been approved by the company's board and supervisory board, ensuring no harm to the interests of shareholders, especially minority shareholders[73]. Research and Development - The company is focused on the research and development of diabetes and endocrine-related drugs, with a comprehensive product line in the diabetes treatment field[24]. - The company has a comprehensive product pipeline in diabetes treatment, including long-acting, medium-acting, and rapid-acting insulin, as well as innovative drugs[32]. - The company is actively expanding its research and development efforts in the endocrine metabolism field, including gout and hyperuricemia[32]. - The company continues to focus on innovative R&D, expanding treatment areas with three new diabetes drugs and two new gout/hyperuricemia drugs in development[42]. - The company has developed a robust R&D pipeline, with two out of five global innovative drugs entering Phase I clinical trials during the reporting period[35]. Market Strategy and Challenges - The impact of national centralized procurement on insulin prices has significantly affected the company's revenue, necessitating adjustments in pricing strategies[19]. - The implementation of national centralized procurement for insulin starting in May 2022 led to a decrease in revenue due to price adjustments and one-time write-offs[29]. - The company aims to enhance its market share by increasing investments in retail channels and private hospitals outside the centralized procurement framework[29]. - The company is facing risks from industry policy changes, particularly due to increased regulatory scrutiny and price reductions from centralized procurement[65]. Environmental Compliance - The company achieved compliance with the emission standards for both wastewater and exhaust gas, with key pollutants meeting regulatory limits[78]. - The company invested over 110 million yuan in environmental protection from 2018 to the first half of 2022, focusing on wastewater treatment upgrades and waste gas treatment facilities[87]. - The company has established an online monitoring system for wastewater discharge, ensuring continuous compliance with environmental standards[78]. - The company is committed to reducing carbon emissions and enhancing resource recycling, with a focus on low-carbon operations[88]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 112,821[104]. - The largest shareholder, Dongbao Industrial Group Co., Ltd., holds 591,699,387 shares, accounting for 29.44% of total shares[105]. - The company completed the repurchase of 23,999,946 shares at a price of 8.29 yuan per share, reducing its registered capital accordingly[101]. - The company has implemented a stock option and restricted stock incentive plan to align the interests of shareholders, the company, and core team members[74]. Financial Position - Total assets at the end of the reporting period were ¥6,912,464,695.87, up 6.02% from the end of the previous year[17]. - The company's cash and cash equivalents at the end of the reporting period amount to RMB 1,078,768,444.66, an increase from RMB 865,039,545.39 at the beginning of the period[111]. - The total liabilities decreased to CNY 176,201,221.90 from CNY 299,874,064.97, a decline of approximately 41%[114]. - The company's retained earnings increased to CNY 3,283,236,981.45 from CNY 2,700,547,905.49, reflecting a growth of around 21.5%[114].